Pius Zängerle – Director, curafutura, Switzerland
Pius Zängerle of curafutura, one of the two largest Swiss health insurers’ associations, explains the unique Swiss health insurance ecosystem and the main issues on his agenda for 2021 beyond…
Intergenerika is Swiss generics association, comprising six companies.
Reimbursable generics achieved sales of 637 million Swiss francs in 2015. Compared with the previous year, the growth amounted to more than seven percent.
The Swiss generics market still has room for further growth and development. In terms of value, the total share of generics within the Swiss pharmaceutical market was 19 percent in 2015 in terms of value, and 32 percent by volume. The member companies of Intergenerika are working hard on the educational front to ensure that pharmacists, doctors and patients have a more balanced view of generics.3
Contact
Telephone +41 61 927 64 08
Altmarktstrasse 96
4410 Liestal
Pius Zängerle of curafutura, one of the two largest Swiss health insurers’ associations, explains the unique Swiss health insurance ecosystem and the main issues on his agenda for 2021 beyond…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head…
Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with…
Professor Susan M. Gasser, now director and group leader emeritus of the Friedrich Miescher Institute for Biomedical Research (FMI), shares the crucial aspects behind the FMI’s world-class reputation in basic…
Dr Chris Martin, CEO and co-founder of Swiss-headquartered antibody-drug conjugate cancer company, ADC Therapeutics, shares the company’s journey over the past decade, the exciting progress of their two lead candidates,…
Giorgio Calderari, the chairman of Farma Industria Ticino, the association of chemical and pharmaceutical industries in the Swiss canton of Ticino, explains how a region with a population of 350,000…
The CEO & President of CDMO CordenPharma, Dr Michael Quirmbach, delves into the contract manufacturing industry, explaining the reasons behind the recent commercial success of his organization, including their partnership…
CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players…
In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical…
AbbVie Switzerland’s Jon Helsdingen outlines how he has led the Swiss affiliate through a full scale office move, the acquisition and integration of Allergan and the COVID-19 pandemic in a…
Mera Pharma’s Khalid Saleh introduces the Swiss-headquartered but MENA-focused company, how it plans to expand via CMOs, and its evolution from food supplements, cosmetics and medical devices into the more…
As part of the Federal Department of Home Affairs, the Federal Office of Public Health (FOPH) is responsible for public health in Switzerland; developing the country’s health policy and working…
See our Cookie Privacy Policy Here
